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1. INTRODUCTION 
WHO characterizes adverse drug reaction (ADR) as any reaction to a 
medication which is harmful and unintended, and which happens at measurements 
typically utilized as a part of man for prophylaxis, analysis or treatment of illness or 
for the alteration of physiological capacity.1 Antagonistic medication responses are 
negative outcomes of medication treatment.2 They are one of the main sources of 
grimness and mortality. It has been assessed that around 2.9-5.6% of all clinic 
affirmations are because of ADRs and upwards of 35% of hospitalized patients 
encounter an ADR amid their hospitalization.3 An unconstrained revealing of ADRs 
has remained the foundation of pharmacovigilance and is imperative in keeping up 
tolerant wellbeing.4 In India, all social insurance experts including specialists, 
medical caretakers, and drug specialists can report an ADR by filling an ADR type 
of the Central Drugs Standard Control Organization.5 The dynamic interest of social 
insurance experts in the pharmacovigilance program can enhance the ADR 
revealing.6 
 The ADR revealing rate in India is underneath 1% contrasted with the 
overall rate of 5%.7 One reason for low reporting rate in India might be an absence 
of learning and sharpening towards pharmacovigilance and ADR among health care 
professionals (HCPs). The examination likewise demonstrated that the normal cost 
associated with treating these ADRs was INR 900/ - per patient.8In India, 
Pharmacovigilance is still in early stage and there exists very limited knowledge 
about this discipline.9Inadequate funds, lack of trained staff, and lack of awareness 
about detection, communication, and spontaneous monitoring of ADRs may be the 
reason, gross underreporting of ADRs is a cause of concern.10 
 The market today is flooded with an enormous number of drugs for various 
ailments. The Pharmaceutical industries are busy innovating testing and 
manufacturing new drugs day in and day out, such that 45 drugs gained FDA 
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approval in 2015 and 41 new drugs were launched in 2014 every year on an 
average.11 Before the drugs are marketed, they undergo stringent measures to assess 
their safety profile; still, certain unusual, rare, serious adverse drug reactions may go 
undetected at this level. This applies more to newer drugs which may lead to severe 
adverse drug reactions which may not have come to light yet owing to a short span 
of their use. ADRs (adverse drug reactions) are responsible for about 5 % to 20% of 
hospital admissions.12About 2.9% ADRs lead to hospitalization and approximately 
6.3% ADRs develop while one is in the hospital.13 One third of these ADRs are 
preventable.14 
 In India, National Pharmacovigilance Centre (NPC) has been formed which 
is an active participant in the on-going activities of UMC and in the past years, the 
PV programme has gained momentum such that the reporting rates from India have 
increased from 0.5% to 2%, still these figures are very low as compared to other 
countries.15All healthcare professionals can report an ADR by filling an ADR 
reporting form provided by CDSCO (Central Drug Standard Control Organization). 
Still, under reporting is highly prevalent. An important part in this under reporting is 
played by the lacunae in the knowledge (especially lack of knowledge of how and 
whom to report about ADRs) and attitude of various health care professionals 
towards monitoring and reporting of ADRs.16 The success of a PV program depends 
upon the active involvement of the healthcare professionals such as doctors, 
pharmacists, nurses and can greatly reduce the burden on limited health care 
resources in developing countries like India.17 
 Increasing health professional and student participation in national 
medication reporting programs remains an important goal in promoting safe health 
care practices. Opportunities for improvement in pharmacy curricula and practice 
sites toward interactive experiences with reporting programs should be continually 
evaluated.18 Thus, early identification of ADRs is extremely important for both 
government and non-government health care organizations. 
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Pharmacovigilance (PV) 
 Pharmacovigilance is concerned with only two outcomes: safety and 
efficacy. Does a drug work and is it safe? It touches on almost every aspect of the 
drug lifecycle - from preclinical development to post-market surveillance - making it 
one of the most fundamental functions within a life science company. 
 Pharmacovigilance – also known as drug safety - is a broad term that 
describes the collection, analysis, monitoring and prevention of adverse effects in 
drugs and therapies. It is a completely scientific and process-driven area within 
pharma. 
The definition of an adverse event is any reaction within a patient’s body 
caused by a drug/candidate molecule – a side effect.  A serious adverse event is a 
life-threatening side effect that causes hospitalisation, incapacity, permanent damage 
or, in extreme cases, the death of a patient. Adverse event reporting is mandatory for 
all clinical research investigators, even if the side effects are only suspected.  
 The role of pharmacovigilance is to determine which adverse events cross 
the line of a drug’s efficacy. In other words, analysing which side effects are worth 
the risk to patients compared with how effective they are at treating a disease. For 
instance, chemotherapy is known to cause some very serious side effects but when 
faced with life-threatening cancer, these side effects are considered acceptable given 
the potential to cure a patient. However, if a drug used to cure a headache caused 
similar side effects, the risk to the patient would be considered too great and the 
benefit not substantial enough to justify the potential damage.     
Main areas of pharmacovigilance 
Pharmacovigilance is a huge and encompassing discipline, but we can 
broadly divide pharmacovigilance into four main sub-specialisms: 
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Operations: 
This sector is where many life science professionals interested in drug safety 
jobs will begin their career. Typical jobs within drug safety operations include case 
processor, drug safety officer/associate and drug safety manager, and of course team 
lead and directorships. These professionals will collect and record information 
during preclinical development and clinical trials, in addition to gathering real world 
evidence (RWE) of adverse events reported by doctors and patients post-market. 
Operations are also usually responsible for creating standard operating procedures 
(SOPs), individual case study reports, literature screening and regulatory expedited 
reporting. 
Surveillance: 
Professionals who focus more within surveillance tend to look towards risk 
management and signal detection jobs. This also involves performing analysis of the 
data collated by the wider division. Professionals in this area can hold an array of 
titles, the most common of which are pharmacovigilance scientist and drug safety 
physician, but like in all teams, there are many degrees of seniority and remit 
available. These professionals perform analysis on the drug safety information 
gathered by the wider department and assist with the creation and review of 
aggregate reports. They also create development safety update reports (DSURs) for 
drugs in clinical research, and periodic benefit risk evaluation reports (PBRER) for 
post-market drugs. These reports ultimately help the team to draw conclusions 
around the safety and efficacy of a drug or candidate molecule.    
Systems 
This division is concerned with the building and ongoing development of a 
fully robust and innovative system, charged with the responsibility for housing and 
allowing access (in various forms) to vast quantities of safety data. This safety data 
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is usually collated by those working in operationally focused roles, but is accessed 
by all. The systems division constantly has to improve, and stay in line with, 
changing regulations and requirements for the business/ health authorities, making 
this a very challenging and vital aspect of drug safety. 
Qualified Person for Pharmacovigilance (QPPV) 
QPPVs jobs are mainly concerned with marketed drugs and those about to be 
authorised, but as QPPVs are considered by many to be subject matter experts, their 
expertise is utilised across the discipline and wider business. These senior 
pharmacovigilance roles will only be held by very experienced professionals and 
their focus is to understand, plan for and advise upon the regulations and 
requirements that companies must adhere to across the EU. This is a highly strategic 
appointment and one of great importance. 
Fortunately for drug safety professionals, there are several 
pharmacovigilance jobs available to them due to the different types of companies 
within life sciences, including global pharmas, small pharmas, generics companies, 
drug safety consultancies and health authorities. Each offers slightly different 
opportunities but in every case, there is plenty of scope for professionals to progress 
their pharmacovigilance career. 
Importance of pharmacovigilance  
Pharmacovigilance is arguably the most essential function within a life 
science company. To develop, manufacture and commercialise a drug a company 
must adhere to strict regulations. Many of these regulations will focus on the 
patient’s safety and the added benefit to the patient derived from the drug. This, in a 
nutshell, is the mission of drug safety and highlights why this discipline plays such a 
central and important role within pharmaceuticals. 
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Patient safety and continuous vigilance 
By definition, drug safety ensures that a patient’s safety and wellbeing is 
safeguarded throughout the entire drug development lifecycle, including when the 
drug is readily available on the market. Indeed, drugs are continuously monitored for 
other side effects on patients, and any new data is collected and reported to health 
authorities on a regular basis. While other areas focus on improving patient lives in 
everything that they do, no other department has such a sharp focus on patient safety 
as an end-point. 
Power and authority 
This continuous vigilance does mean that, alongside others in the business, 
senior leaders within a drug safety team have the responsibility and authority to 
recommend that a development process is stopped, or that an approved drug is 
pulled from the market. EU QPPVs are especially important in this process, and 
again this goes to demonstrate the importance and central role of drug safety. 
Keeping it moving 
In many ways, drug safety helps to keep the wheels of a pharmaceutical 
company moving. The nature of drug safety means that it works on a very cross-
functional basis. Therefore, the influence and value which the division can add to 
other aspects of the business is tremendous.19 
Adverse event reporting 
The activity that is most commonly associated with pharmacovigilance (PV), 
and which consumes a significant amount of resources for drug regulatory 
authorities (or similar government agencies) and drug safety departments in 
pharmaceutical companies, is that of adverse event reporting. Adverse event (AE) 
reporting involves the receipt, triage, data entering, assessment, distribution, 
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reporting (if appropriate), and archiving of AE data and documentation. The source 
of AE reports may include: spontaneous reports from healthcare professionals or 
patients (or other intermediaries); solicited reports from patient support programs; 
reports from clinical or post-marketing studies; reports from literature sources; 
reports from the media (including social media and websites); and reports reported 
to drug regulatory authorities themselves. For pharmaceutical companies, AE 
reporting is a regulatory requirement in most countries. AE reporting also provides 
data to these companies and drug regulatory authorities that play a key role in 
assessing the risk-benefit profile of a given drug. The following are several facets of 
AE reporting: 
Individual Case Safety Report (ICSR) 
One of the fundamental principles of adverse event reporting is the 
determination of what constitutes an Individual Case Safety Report (ICSR). During 
the triage phase of a potential adverse event report, it is important to determine if the 
"four elements" of a valid ICSR are present: an identifiable patient, an identifiable 
reporter, a suspect drug, and an adverse event. 
If one or more of these four elements is missing, the case is not a valid ICSR. 
Although there are no exceptions to this rule there may be circumstances that may 
require a judgment call. For example, the term "identifiable" may not always be 
clear-cut. If a physician reports that he/she has a patient X taking drug Y who 
experienced Z (an AE), but refuses to provide any specifics about patient X, the 
report is still a valid case even though the patient is not specifically identified. This 
is because the reporter has first-hand information about the patient and is identifiable 
(i.e. a real person) to the physician. Identifiability is important so as not only to 
prevent duplicate reporting of the same case, but also to permit follow-up for 
additional information. 
Assessment of Knowledge, attitude and practice of pharmacovigilance and adverse drug reaction 
reporting among nursing staff 
 
Department of Pharmacy Practice                        8           JKK Nattraja College of Pharmacy 
 
The concept of identifiability also applies to the other three elements. 
Although uncommon, it is not unheard of for fictitious adverse event "cases" to be 
reported to a company by an anonymous individual (or on behalf of an anonymous 
patient, disgruntled employee, or former employee) trying to damage the company's 
reputation or a company's product. In these and all other situations, the source of the 
report should be ascertained (if possible). But anonymous reporting is also 
important, as whistle blower protection is not granted in all countries. In general, the 
drug must also be specifically named. Note that in different countries and regions of 
the world, drugs are sold under various tradenames. In addition, there are a large 
number of generics which may be mistaken for the trade product. Finally, there is 
the problem of counterfeit drugs producing adverse events. If at all possible, it is 
best to try to obtain the sample which induced the adverse event, and send it to 
either the EMA, FDA or other government agency responsible for investigating AE 
reports. 
If a reporter can't recall the name of the drug they were taking when they 
experienced an adverse event, this would not be a valid case. This concept also 
applies to adverse events. If a patient states that they experienced "symptoms", but 
cannot be more specific, such a report might technically be considered valid, but 
will be of very limited value to the pharmacovigilance department of the company 
or to drug regulatory authorities.20 
Coding of adverse events 
Adverse event coding is the process by which information from an AE 
reporter, called the "verbatim", is coded using standardized terminology from a 
medical coding dictionary, such as MedDRA (the most commonly used medical 
coding dictionary). The purpose of medical coding is to convert adverse event 
information into terminology that can be readily identified and analyzed. For 
instance, Patient 1 may report that they had experienced "a very bad headache that 
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felt like their head was being hit by a hammer" [Verbatim 1] when taking Drug X. 
Or, Patient 2 may report that they had experienced a "slight, throbbing headache that 
occurred daily at about two in the afternoon" [Verbatim 2] while taking Drug Y. 
Neither Verbatim 1 nor Verbatim 2 will exactly match a code in the MedDRA 
coding dictionary. However, both quotes describe different manifestations of a 
headache. As a result, in this example both quotes would be coded as PT Headache 
(PT = Preferred Term in MedDRA). 
Seriousness determination 
Although somewhat intuitive, there are a set of criteria within 
pharmacovigilance that are used to distinguish a serious adverse event from a non-
serious one. An adverse event is considered serious if it meets one or more of the 
following criteria: results in death, or is life-threatening;requires inpatient 
hospitalization or prolongation of existing hospitalization;   results in persistent or 
significant disability or incapacity;results in a congenital anomaly (birth defect); oris 
otherwise "medically significant" (i.e., that it does not meet preceding criteria, but is 
considered serious because treatment/intervention would be required to prevent one 
of the preceding criteria).20 
Aside from death, each of these categories is subject to some interpretation. 
Life-threatening, as it used in the drug safety world, specifically refers to an adverse 
event that places the patient at an immediate risk of death, such as cardiac or 
respiratory arrest. By this definition, events such as myocardial infarction, which 
would be hypothetically life-threatening, would not be considered life-threatening 
unless the patient went into cardiac arrest following the MI. Defining what 
constitutes hospitalization can be problematic as well. Although typically 
straightforward, it's possible for a hospitalization to occur even if the events being 
treated are not serious. By the same token, serious events may be treated without 
hospitalization, such as the treatment of anaphylaxis may be successfully performed 
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with epinephrine. Significant disability and incapacity, as a concept, is also subject 
to debate. While permanent disability following a stroke would no doubt be serious, 
would "complete blindness for 30 seconds" be considered "significant disability"? 
For birth defects, the seriousness of the event is usually not in dispute so much as 
the attribution of the event to the drug. Finally, "medically significant events" is a 
category that includes events that may be always serious, or sometimes serious, but 
will not fulfill any of the other criteria. Events such as cancer might always be 
considered serious, whereas liver disease, depending on its CTCAE (Common 
Terminology Criteria for Adverse Events) grade—Grades 1 or 2 are generally 
considered non-serious and Grades 3-5 serious—may be considered non-serious.21 
Expedited reporting 
This refers to ICSRs (individual case safety reports) that involve a serious 
and unlisted event (an event not described in the drug's labeling) that is considered 
related to the use of the drug. (Spontaneous reports are typically considered to have 
a positive causality, whereas a clinical trial case will typically be assessed for 
causality by the clinical trial investigator and/or the license holder.) In most 
countries, the timeframe for reporting expedited cases is 7/15 calendar days from the 
time a drug company receives notification (referred to as "Day 0") of such a case. 
Within clinical trials such a case is referred to as a SUSAR (a Suspected Unexpected 
Serious Adverse Reaction). If the SUSAR involves an event that is life-threatening 
or fatal, it may be subject to a 7-day "clock". Cases that do not involve a serious, 
unlisted event may be subject to non-expedited or periodic reporting. 
Clinical trial reporting 
Also known as SAE (serious adverse event) reporting from clinical trials, 
safety information from clinical studies is used to establish a drug's safety profile in 
humans and is a key component that drug regulatory authorities consider in the 
decision-making as to whether to grant or deny market authorization (market 
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approval) for a drug. SAE reporting occurs as a result of study patients (subjects) 
who experience serious adverse events during the conducting of clinical trials. (Non-
serious adverse events are also captured separately.) SAE information, which may 
also include relevant information from the patient's medical background, are 
reviewed and assessed for causality by the study investigator. This information is 
forwarded to a sponsoring entity (typically a pharmaceutical company) that is 
responsible for the reporting of this information, as appropriate, to drug regulatory 
authorities. 
Spontaneous reporting 
Spontaneous reports are termed spontaneous as they take place during the 
clinician's normal diagnostic appraisal of a patient, when the clinician is drawing the 
conclusion that the drug may be implicated in the causality of the event. 
Spontaneous reporting system relies on vigilant physicians and other healthcare 
professionals who not only generate a suspicion of an ADR, but also report it. It is 
an important source of regulatory actions such as taking a drug off the market or a 
label change due to safety problems. Spontaneous reporting is the core data-
generating system of international pharmacovigilance, relying on healthcare 
professionals (and in some countries consumers) to identify and report any adverse 
events to their national pharmacovigilance center, health authority (such as EMA or 
FDA), or to the drug manufacturer itself.22 Spontaneous reports are, by definition, 
submitted voluntarily although under certain circumstances these reports may be 
encouraged, or "stimulated", by media reports or articles published in medical or 
scientific publications, or by product lawsuits. In many parts of the world adverse 
event reports are submitted electronically using a defined message standard.23 
One of the major weaknesses of spontaneous reporting is that of under-
reporting, where, unlike in clinical trials, less than 100% of those adverse events 
occurring are reported. Further complicating the assessment of adverse events, AE 
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reporting behavior varies greatly between countries and in relation to the seriousness 
of the events, but in general probably less than 10% (some studies suggest less than 
5%) of all adverse events that occur are actually reported. The rule-of-thumb is that 
on a scale of 0 to 10, with 0 being least likely to be reported and 10 being the most 
likely to be reported, an uncomplicated non-serious event such as a mild headache 
will be closer to a "0" on this scale, whereas a life-threatening or fatal event will be 
closer to a "10" in terms of its likelihood of being reported. In view of this, medical 
personnel may not always see AE reporting as a priority, especially if the symptoms 
are not serious. And even if the symptoms are serious, the symptoms may not be 
recognized as a possible side effect of a particular drug or combination thereof. In 
addition, medical personnel may not feel compelled to report events that are viewed 
as expected. This is why reports from patients themselves are of high value. The 
confirmation of these events by a healthcare professional is typically considered to 
increase the value of these reports. Hence it is important not only for the patient to 
report the AE to his health care provider (who may neglect to report the AE), but 
also report the AE to both the biopharmaceutical company and the FDA, EMA. This 
is especially important when one has obtained one's pharmaceutical from a 
compounding pharmacy. 
As such, spontaneous reports are a crucial element in the worldwide 
enterprise of pharmacovigilance and form the core of the World Health Organization 
Database, which includes around 4.6 million reports (January 2009), growing 
annually by about 250,000.22 
Aggregate reporting 
Aggregate reporting, also known as periodic reporting, plays a key role in the 
safety assessment of drugs. Aggregate reporting involves the compilation of safety 
data for a drug over a prolonged period of time (months or years), as opposed to 
single-case reporting which, by definition, involves only individual AE reports. The 
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advantage of aggregate reporting is that it provides a broader view of the safety 
profile of a drug. Worldwide, the most important aggregate report is the Periodic 
Safety Update Report (PSUR) and Development Safety Update Report (DSUR). 
This is a document that is submitted to drug regulatory agencies in Europe, the US 
and Japan (ICH countries), as well as other countries around the world. The PSUR 
was updated in 2012 and is now referred to in many countries as the Periodic 
Benefit Risk Evaluation report (PBRER). As the title suggests, the PBRER's focus is 
on the benefit-risk profile of the drug, which includes a review of relevant safety 
data compiled for a drug product since its development. 
Other reporting methods 
Some countries legally oblige spontaneous reporting by physicians. In most 
countries, manufacturers are required to submit, through its Qualified Person for 
Pharmacovigilance (QPPV), all of the reports they receive from healthcare providers 
to the national authority. Others have intensive, focused programmes concentrating 
on new drugs, or on controversial drugs, or on the prescribing habits of groups of 
doctors, or involving pharmacists in reporting. All of these generate potentially 
useful information. Such intensive schemes, however, tend to be the exception.23 
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2. LITERATURE REVIEW 
Nisa24et al., (2018)evaluated a study to assess the knowledge, attitude, 
practice and factors associated with ADR reporting by healthcare professionals 
(physicians and pharmacists) in secondary and tertiary hospitals of Islamabad. A 
pretested questionnaire comprising of 27 questions (knowledge 12, attitude 4, 
practice 9 and factors influencing ADR reporting 2) was administered to 384 
physicians and pharmacists in public and private hospitals. Respondents were 
evaluated for their knowledge, attitude and practice related to ADR reporting. 
Additionally, the factors which encourage and discourage respondents to report 
ADRs were also determined. The data was analysed by using SPSS statistical 
software. Among 384 respondents, 367 provided responses to questionnaire, giving 
a response rate of 95.5%. The mean age was 28.3 (SD = 6.7). Most of the 
respondents indicated poor ADR reporting knowledge (83.1%). The majority of 
respondents (78.2%) presented a positive attitude towards ADR reporting and only a 
few (12.3%) hospitals have good ADR reporting practice. The seriousness of ADR, 
unusualness of reaction, new drug involvement and confidence in the diagnosis of 
ADR are the factors which encourage respondents to report ADR whereas lack of 
knowledge regarding where and how to report ADR, lack of access to ADR 
reporting form, managing patient is more important than reporting ADR legal 
liability issues were the major factors which discourage respondents to reportADR. 
The study reveals poor knowledge and practice regarding ADR reporting. However, 
most of the respondents have shown a positive attitude towards ADR reporting. 
There is a serious need for educational training as well as sincere and sustained 
efforts should be made by Government and Hospital Authorities to ensure proper 
implementation of ADR reporting system in all of the hospitals.  
Farha25et al., (2018)conducted a study in Jordan University Hospital on 
various healthcare providers to assess their pre- and post-knowledge and perception 
towards pharmacovigilance and adverse drug reactions (ADRs) reporting via 
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questionnaire before and after an educational workshop. Among the 200 invited 
healthcare providers, 150 attended the educational workshop (response rate 75.0%). 
Pre-workshop, healthcare providers showed an overall low knowledge score 
(7.8/19), where only 8.7% could define pharmacovigilance correctly. On the other 
hand, they showed a favorable perception score (33.6/39).  Following educational 
workshop, knowledge scores significantly improved by 67.9% (P-value <0.05). A 
similar finding was obtained for perception scores, where perception scores 
significantly improved by 10.1% following workshop (P-value <0.05). Continuous 
efforts are needed to implement different strategies including education modules and 
the provision of appropriate training programs to increase awareness and improve 
perception towards pharmacovigilance among healthcare providers. Future study is 
needed to evaluate the impact of improving knowledge and perception on ADRs 
reporting practice. 
Alshammari26et al., (2018)conducted a cross-sectional survey between 
January and February of 2013 in nine tertiary care hospitals (governmental and 
private) that provide highly specialized medical services in Riyadh, Qassim, and the 
Eastern region of the Kingdom of Saudi Arabia. A validated questionnaire was used 
to assess the knowledge, attitudes, and practices of HCPs regarding the ADR 
reporting system. All statistical analyses were performed using SAS version 9.2.  In 
total, 480 questionnaires were distributed, and the response rate was 70% (n = 336). 
Only 33% of the participants were aware of the National Pharmacovigilance Centre 
(NPC). Of those HCPs who were familiar with the NPC and their responsibility to 
report ADRs, most (50%) were pharmacists, followed by physicians (24%) and 
nurses (16%), and these differences were statistically significant (p < 0.01). 
Twentyseven percent of the participants were involved in reporting ADRs; among 
these HCPs, 62% were pharmacists, 26% were nurses, and 6% were physicians. 
Most participants (95%) favoured reporting ADRs caused by antibiotics and new/old 
drugs. The prominent factors discouraging ADR reporting included fear that the 
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report might be incorrect (46%) and lack of time (44%).  A significant lack of 
knowledge, positive attitudes, and practices regarding ADRs and reporting was 
observed in hospital HCPs. This finding represents an international concern, and 
urgent action is needed to promote drug safety and pharmacovigilance in this region. 
Keerthana27et al., (2017) undertaken a study to evaluate the knowledge, 
attitude, and practices (KAP) regarding ADR reporting among prescribers. Materials 
and methods: A pretested KAP questionnaire comprising of 17 questions was 
administered to 63 prescribers. The questionnaires were assessed for their 
completeness and the type of responses regarding ADR reporting. Result and 
discussion: A total of 63 prescribers completed the survey. ADR reporting was 
considered important by 51.9 % of the respondents; primarily to share Information 
about ADR with colleagues(37.3%). A majority of the respondents opined that they 
would like to report serious ADRs (31.1%). 93.3% of the prescribers had reported 
ADRs in their practise. Preferred methods for reporting were post(32.2%). The 
prescribers are aware of the ADRs and the importance of their reporting. However, 
under reporting and lack of knowledge about the reporting system are clearly 
evident. Creating awareness about ADR reporting and devising means to make it 
easy and convenient may aid in improving spontaneous reporting.  
Sharrad28et al., (2017) evaluated the knowledge, attitude and practices 
(KAP) of the pharmacists towards ADRs and pharmacovigilance in Basra Hospitals. 
A cross-sectional analytical study was carried out in the province of Basra. All the 
pharmacists present in the Basra province during the study period were enrolled in 
the study and the convenience sampling technique was utilized for analysis. Hence, 
530 pharmacists took part in the study. This questionnaire was tested and made 
error-free prior to using. This questionnaire contained 5 knowledge-based questions, 
5-attitude related questions and tow questions which were related to the practices 
used towards the ADRs. The response rate was 24.9 %.The results of our study 
clearly point out that in spite of the pharmacists positive attitude there was a lack of 
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appropriate knowledge and practice to implement ADRs reporting successfully. The 
results emphasized the critical need for interventions to support ADRs reporting 
activity and to maintain Pharmacist’s positive attitude. Our findings suggested that 
the need for positive evidence based on educational and managerial interventions 
regularly to improve ADR reporting. It would be more beneficial, if the Ministry of 
higher education would suggest some more measures to review and perhaps improve 
pharmacy colleges’ curricula to guarantee the incorporation of PV and ADRs 
reporting system conception. 
Sharrad29et al., (2017)evaluated the knowledge, attitude and practice 
towards reporting of ADR and pharmacovigilance among final year students 
studying in the college of pharmacy at a public university in Basra. This 
questionnaire was tested and made error-free prior to using. This questionnaire 
contained ten knowledge-based questions, five attitude related questions and two 
questions which were related to the practices used towards the ADRs. The 
participants were interviewed and data was collected. A total of 83 respondents 
participated in the study. The mean knowledge score of pharmacovigilance and 
ADR reporting for the final year pharmacy students was 6.26 + 1.56.In general, the 
participants had a good attitude towards ADRs. Most of the participants of the 
survey, i.e., 96.3% (80), did not attend in any ADR workshop or training course. 
Most of the participants of the survey, i.e., 95.1% (79), did not have any idea about 
ADR reporting process. It was concluded from the results that the 
Pharmacovigilance plays an important role in safe and effective use of drugs in a 
situation which arises after the marketing and sales of drugs. Regarding the research, 
the pharmacy students displayed relatively modest knowledge and positive attitude 
but inadequate practice regarding ADRs and pharmacovigilance. There is a 
requirement for continuous learning strategy for the pharmacists. 
Alsaleh30et al., (2017) study documented the knowledge, attitude and 
practices (KAP) of pharmacists toward PV and ADR reporting and to explore the 
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barriers to implementing a fully functional PV program in Kuwait. Pharmacists 
working at governmental hospitals were asked to complete a paper-based 25-item 
questionnaire. A total of 414 pharmacists received the questionnaire and 342 agreed 
to participate, giving a response rate of 82.6%. Most pharmacists were 
knowledgeable about the concepts of PV (61.5%) and ADRs (72.6%) and the 
majority (88.6%) was willing to implement ADR reporting in their clinical practice. 
Despite this positive attitude, only 26.8% of participants had previously reported an 
ADR and the main reason for underreporting were stated as not knowing how to 
report (68.9%). Barriers that hinder the implementation of a PV center included lack 
of cooperation and communication by healthcare professionals and patients (n = 62), 
lack of time and proper management (n = 57), lack of awareness of staff and patients 
(n = 48) and no qualified person to report ADRs (n = 35). Overall this study shows 
that hospital pharmacists in Kuwait had good knowledge and positive attitude 
toward PV and ADRs reporting. However, the majority of them have never reported 
ADRs. These results suggest that targetededucational interventions and a well-
defined policy for ADR reporting may help increase ADR reporting and support the 
implementation of a fully functional independent PV center in Kuwait 
Tew31et al., (2016)study was aimedto investigate the KAP towards ADR 
reporting among HCPs working at primaryoutpatient care in Kuala Muda District 
Health Office, Kedah, Malaysia.A cross sectional study was done by survey using a 
self-administered structured questionnaire.The questionnaire was distributed to all 
healthcare professionals working at primary outpatient care.The overall response 
rate was 87.4%. The mean knowledge score was 66.9% ± 19.86for doctors and 
76.9% ± 13.87 for pharmacists (p=0.03). 43.8% of the healthcare professionals did 
not aware of theblue card reporting system in Malaysia. Almost all of the 
respondents agreed that ADR reporting should be mademandatory and they 
recognized that it's their professional obligation to report any ADR. However, only 
51.9% ofdoctors and 70.8 % of pharmacist had reported. Half of the respondents 
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professed that ADR forms are too complexto fill and almost all of the respondents 
(90.4% doctors and 87.5% pharmacists) declared that they are lacking oftime to fill 
in the report. 69.2% of doctors expressed that they have not been trained on ADR 
reporting which wascontradicting with the pharmacists (12.5%) (p<0.001). Almost 
all respondents (82.7 % doctors and 95.8pharmacists) concurred that ADR reporting 
should be taught in details to them.Respondents reflected inadequate knowledge on 
ADR reporting. The prevalence of unsatisfactorypractices and attitudes among these 
HCPs contributed to failure to report ADR even if the ADR was 
identified.Educational intervention strategies can be introduced in order to promote 
ADR reporting. 
Sah32et al., (2017) study was planned to assess the knowledge, attitude and 
practices of PhV among community pharmacist in Delhi, India. Cross sectional, 
questionnaire based study was conducted to evaluate the knowledge, attitude and 
practice of PhV among 200 community pharmacists of Delhi (west Delhi) India. 
Majority (74%) of the respondents felt that ADR reporting is necessary but only 9% 
were aware of existing PhV Program of India. Only 5% of pharmacists knew about 
elements of PhV. Forty percent (40%) of pharmacists did not know where to report 
ADRs and 26% felt that there is no need to report ADRs. Significant number (77%) 
of pharmacists felt that ADRs reporting will damage their image. 96% never try to 
find ADRs and in case if they get ADRs from patients, majority (95%) of them 
never report to anybody. Almost all (96%) of respondents cited busy schedule as the 
main reason for non-reporting and 86% said that it will be very convenient if ADRs 
are collected by someone from them. Community pharmacists had positive attitude 
towards ADRs reporting but their knowledge and practice regarding PhV need to be 
improved. There is a need of regular training to increase their role in PhV. 
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Srinivasan33et al., (2017)conducted a study to identify the possible factors 
responsible for underreporting (UR) of adverse drug reactions (ADRs) and 
encourage the healthcare professionals to substantiate the Pharmacovigilance 
Programme of India (PvPI). The present study was a cross-sectional questionnaire-
based study to assess the knowledge, attitude, and practice (KAP) of 
pharmacovigilance among practicing healthcare professionals working in the 
Saveetha Medical College & Hospital, Thandalam, Chennai. The statistical analysis 
was done using Statistical Package for Social Sciences (SPSS) version 23 software. 
The result shows difference in explicit knowledge and tacit knowledge among 
healthcare professionals. Attitude questions have identified the affective behaviour 
of the respondents and practice questions shows evidence of a paradigm shift 
towards an organized pharmacovigilance constructivism. KAP of the healthcare 
professionals highlights the under-reporting of ADR; Multimodality interventions 
are needed to improve spontaneous ADR reporting. 
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3. NEED OF THE STUDY 
 The most serious ADRs lead to hospitalization, and hospital stays can lead to 
further ADRs. Hence, HCPs and hospitals can play a significant role in minimizing 
ADR-related morbidity and mortality.34 HCPs can play multiple roles by carefully 
reviewing the full patient history, particularly the drug allergy and drug-drug 
interaction history, to avoid any unwanted ADRs. In addition, reporting ADRs to the 
responsible office at their hospital or the regulatory authority is a pharmacovigilance 
approach that can be used to minimize ADRs because reporting ADRs can increase 
HCPs’ awareness of reactions, which could result in the avoidance of particular 
drugs, thus reducing the harm associated with reactions to particular drugs.35 
Several drugs have been withdrawn from the market as a result of HCPs 
reporting ADRs.35 However, understanding the knowledge and practice of health 
care professionals regarding ADR reporting is very important for enhancing the 
reporting of ADRs.36 
 Therefore, the present study is undertaken to determine the current status of 
ADR reporting and also to investigate knowledge and attitude of particularly nursing 
staffs towards pharmacovigilance and ADR reporting. 
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4. AIM AND OBJECTIVES 
AIM 
o To assess the knowledge, attitude and practice of pharmacovigilance and 
adverse drug reaction reporting among nursing staffs. 
OBJECTIVES 
o To assess the knowledge of pharmacovigilance towards adverse drug 
reaction reporting 
o To assess the attitude and practice towards adverse drug reaction reporting 
o To determine the factors that encourages the study subjects to report adverse 
drug reaction 
o To evaluate the factors that discourages the study subjects not to report 
adverse drug reaction 
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5. PLAN OF THE WORK 
The entire study was conducted out for a period of 10 months. The study was 
designed as given below:  
Phase I 
 Conduct literature review 
 Design questionnaire form and patient consent form.  
 Obtain the approval from the institutional ethical committee and hospital 
authority 
Phase II 
 Collect participant’s demographical information 
 Collect KAP questionnaire towards pharmacovigilance and adverse drug 
reaction 
Phase III 
 Data analysis  
 Submission of report 
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6. METHODOLOGY 
Study site 
 The study was conducted in 3 different multi-speciality hospitals, at Chennai. 
Study design 
 Cross sectional, questionnaire based study 
Study setting 
 This study was conducted from December 2017 to August 2018 for a period 
of 10 months. 
Study sample 
 The study sample size was 300. 
Inclusion criteria 
 Nurses 
 Any age group 
Exclusion criteria 
 Other health care professionals 
 Study participants with unwillingness are excluded 
Study tools 
The study questionnaire was prepared for incorporating participant’s 
demographic details like age, gender and designation and working experiences. In 
KAP, Knowledge part of the questionnaire included sixteen questions that were used 
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to measure the knowledge of nurses related to ADR and pharmacovigilance such as 
definition, awareness, purpose of ADR, PV, reporting system, regulatory body etc. 
The attitude part comprised of eight questions about their thoughts and views related 
to ADR and reporting. Attitudes related questions were developed in 5-point likert 
scale. The practice part of questionnaire included three questions such as type, 
nature, methods for ADR reporting. Finally the fifth section was limited to two 
questions with the help of which factors encouraging and discouraging to nurses to 
report ADR were determined. 
Data collection 
A structured pretested questionnaire was prepared. After pilot-scale testing, 
the questionnaire was modified. After obtaining approval from IEC and hospital 
authority, a questionnaire was distributed to nursing staffs.Participants were 
explained about the purpose of the study. Those who showed interest to participate 
in the study were requested to fill the questionnaire in 30 min with ensured 
confidentiality. The responses to the questionnaire were analyzed, categorized and 
presented in percentages. 
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7. RESULTS 
Table 1: Gender wise distribution of participants 
Gender 
Total no of participants 
n= 151(%) 
Female 144(95.3%) 
Male 7(4.63%) 
 
 
 
Figure 1: Gender wise distribution of participants 
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Table 2: Age wise distribution of participants 
Age group in years 
Total no of participants 
n= 151 (%) 
16-20 0 
21-25 112(74.1%) 
26-30 26(17.2%) 
31 and above 13(8.6%) 
 
 
 
Figure 2:  Age wise distribution of participants 
 
 
0 
112 
26 
13 
0
20
40
60
80
100
120
16-20 21-25 26-30 31 and above
To
ta
l 
n
o
 o
f 
p
a
rt
ic
ip
a
n
ts
 
Age group in years 
Assessment of Knowledge, attitude and practice of pharmacovigilance and adverse drug reaction 
reporting among nursing staff 
 
Department of Pharmacy Practice                        28           JKK Nattraja College of Pharmacy 
 
 
Table 3: Experience wise distribution of participants 
Working 
Experience in years 
Total no of participants 
n=151 (%) 
<1 2(1.3%) 
1-5 132(87.4%) 
6-10 10(6.6%) 
11-15 0 
16-20 0 
>21 7(4.6%) 
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Table 4: Grade/Rank wise distribution of participants 
 Designation Total no of participants 
n=151(%) 
Beginner/junior 3(1.9%) 
Nurse 139(92%) 
Senior Nurse 1(0.6%) 
Nurse specialist 5(0.3%) 
Senior nurse specialist 2(0.1%) 
Head of nurse 1(0.6%) 
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Table 5: Awareness status 
Awareness status 
Total no of participants 
n=151(%) 
Have you attended any program/seminar relate to PV 
Yes 147(97.3%) 
No 4(2.6%) 
 
 
 
Figure 5: Knowledge towards ADR/PV 
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Table 6: Knowledge towards ADR/PV 
S.No Question regarding knowledge 
Respondent 
response n= 151 
(%) 
1 
Pharmacovigilance 
a) The science of monitoring ADR’s happening in a 
hospital  
b) The process of improving the safety of drugs  
c) The detection, assessment, understanding and 
prevention of adverse effects  
d) The science detecting the type and incidence of 
ADR after the drug is marketed  
e) Do not know 
 
94 (62.2%) 
21(13.9%) 
30(19.8%) 
 
2(1.3%) 
 
4(2.6%) 
2 
ADR 
a) Noxious and unintended response to drug and 
occurs at doses normally used in man or animal 
for prophylaxis, diagnosis or therapy of disease 
b) Noxious and unintended response to drug and 
occurs at doses normally used in man for 
prophylaxis, diagnosis and therapy of disease  
c) Any untoward medical occurrence that may 
present during treatment with a medicine but 
which does not necessarily have a causal 
relationship with this treatment 
d) Any adverse reaction identified in regulatory 
documents such as investigators brochures or 
product monograph occurring within the expected 
frequency 
e) Do not know  
 
 
64 (42.3%) 
 
 
21 (13.9%) 
 
 
46 (30.4%) 
 
 
15 (9.9%) 
 
 
5 (3.3%) 
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S.No Question regarding knowledge 
Respondent 
response n= 151 
(%) 
3 
Are you aware of any formal reporting system available 
in other countries  
a) Yes  
b) No 
 
 
116(76.8%) 
35(23.1%) 
4 
Are you aware of any drug that has been banned in the 
world due to ADR? 
a) Yes  
b) No  
c) Do not know  
 
 
18(11.9%) 
23(15.2%) 
110(72.8%) 
5 
Have you ever shared information about ADRs with 
anyone? 
a) Yes  
b) No  
 
8(5.3%) 
143(94.7%) 
6 
Where is an international centre for adverse effect 
reaction monitoring located? 
a) Sweden  
b) Germany  
c) USA  
d) Do not know  
 
 
12(7.9%) 
28(18.5%) 
65(43%) 
46(30.4%) 
7 
Which of the following is a major risk factor for the 
occurrence of maximum adverse drug reactions? 
a) Arthritis  
b) Renal failure  
c) Visual impairment  
d) All of these  
e) Do not know  
 
 
24(15.8%) 
64(42.3%) 
16(10.5%) 
5(3.3%) 
42(27.8%) 
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S.No Question regarding knowledge 
Respondent 
response n= 151 
(%) 
8 
Are you aware of any of the below reporting centre or 
system in India where you can report ADR? 
a) Madras Medical College, Chennai   
b) Christian Medical College, Vellore  
c) PSG institute, Coimbatore 
d) Govt. Kilpauk Medical College, Chennai  
e) Ministry of health  
f) No centre for reporting  
g) Do not know  
 
 
43(28.4%) 
5(3.3%) 
0(%) 
50(33%) 
41(27.1%) 
0(%) 
12(7.9%) 
9 
Identify the types of ADR’s?  
a) Type A, B, C, D, E, F and G  
b) Type 1, 2, 3, 4, 5, 6 and 7  
c) Known, unknown and common, uncommon  
d) Reversible and irreversible  
e) Do not know  
 
0(%) 
0(%) 
0(%) 
0(%) 
151(100%) 
10 
Which one of the following is the WHO online database 
for reporting ADR’s? 
a) ADR advisory committee  
b) Med safe  
c) Vigibase 
d) Med watch  
e) Do not know  
 
 
64(42.3%) 
24(15.8%) 
12(7.9%) 
30(19.8%) 
21(13.9%) 
11 
From which sources do you gather information about 
ADRs to new drugs? 
a) Textbooks  
b) Journals  
c) Internet  
d) Medical representatives  
e) Seminars/conferences  
 
 
15(9.9%) 
2(1.3%) 
23(15.2%) 
3(1.9%) 
78(51.6%) 
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S.No Question regarding knowledge 
Respondent 
response n= 151 
(%) 
f) Direct mail brochures  
g) All of the above  
0(%) 
30(19.8%) 
12 
Side effects like headache, fever and vomiting should 
not be reported? 
a) Strongly agree  
b) Agree  
c) Disagree  
d) Strongly disagree  
 
 
21(13.9%) 
84(55.6%) 
40(26.4%) 
6(3.9%) 
13 
What to report:  
a) Serious adverse event (SAE)  
b) Adverse Event  
c) Adverse drug reaction (ADR)  
d) Side Effect  
e) All  
f) Not know 
 
12(7.9%) 
8(5.2%) 
32(21.1%) 
84(55.6%) 
9(5.9%) 
6(3.9%) 
14 
Which ADR should be reported 
a) All serious ADRs 
b) ADRs to herbal and non-allopathic drugs 
c) ADRs to new drugs 
d) ADRs to vaccines 
e) Unknown ADRs to odd drugs 
f) All of the above 
 
123(81.4%) 
0(%) 
0(%) 
0(%) 
14(9.2%) 
14(9.2%) 
15 
In India which Regulatory body is responsible for 
monitoring of ADR’s?  
a) Central Drugs Standard Control Organization*  
b) Indian Institute of sciences  
c) Pharmacy Council of India  
d) Medical Council of India 
 
 
4(2.6%) 
57(37.7%) 
68(45%) 
22(14.5%) 
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S.No Question regarding knowledge 
Respondent 
response n= 151 
(%) 
16 
Pharmacovigilance includes  
a) Drug related problems  
b) Blood related products  
c) Herbal products  
d) All of the above 
 
67(44.3%) 
0(%) 
23(15.2%) 
61(40.3%) 
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Table 7: Attitude towards ADR reporting 
Attitude towards ADR 
Total no of participants n= 151 (%) 
Strongly 
agree Agree Disagree 
Strongly 
disagree 
ADR reporting necessary 126(83.4%) 25(16.5%) 0(%) 0(%) 
ADR reporting should be 
mandatory 136(90%) 15(9.9%) 0(%) 0(%) 
ADR reporting increase 
patient safety 131(86.7%) 20(13.2%) 0(%) 0(%) 
ADR is time consuming 110(72.8%) 25(16.5%) 8(5.2%) 8(5.2%) 
Do you think it is necessary to 
confirm that an ADR is 
related to a particular drug 
before reporting it? 
8(5.2%) 131(86.7%) 12(7.9%) 0(%) 
Education programs have 
positive effect on ADRs 
reporting 
148(98%) 3(1.9%) 0(%) 0(%) 
Consulting the physician is 
important before report an 
ADR 
63(41.7%) 53(35%) 35(23.1%) 0(%) 
With my present knowledge, I 
am very well prepared to 
report any ADRs notice in my 
future practice. 
8(5.2%) 84(55.6%) 10(6.6%) 49(32.4%) 
Do you think 
Pharmacovigilance should be 
taught in detail to healthcare 
professionals? 
151(100%) 0(%) 0(%) 0(%) 
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Table 8: Practice towards ADR reporting    
Practice Yes No 
Have you reported any ADR 89(59%) 62(41%) 
 
 
 
Figure 6: Practice towards ADR reporting    
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Table 9: Distribution of nature of ADR  
Nature of ADR reported Total no. of participants n= 89 (%) 
Severe 84(94.3%) 
Moderate 26(29.2%) 
Mild 51(57.3%) 
All of the above 0(%) 
 
 
 Figure 7: Distribution of nature of ADR 
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Table 10: Practice towards ADR prevention    
Practice Yes No 
Have you done any intervention to 
prevent ADRs  
0(%) 89(58.9%) 
 
 
Figure 8: Practice towards ADR prevention    
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Table 11: Distribution of ADR reporting centre  
ADR reporting  centre by 
respondents 
Total no. of participants n= 151(%) 
Colleagues/ immediate reporting 119(78.8%) 
Head of department 20(13.2%) 
Ministry of health 0(%) 
Do not know 12(7.9%) 
 
 
Figure 9: Distribution of ADR reporting centre 
 
 
119 
20 
0 
12 Colleagues/ immediate
reporting
Head of department
Ministry of health
Do not know
Assessment of Knowledge, attitude and practice of pharmacovigilance and adverse drug reaction 
reporting among nursing staff 
 
Department of Pharmacy Practice                        41           JKK Nattraja College of Pharmacy 
 
 
Table 12: Distribution of preferred methods of ADR reporting 
Preferred methods to report 
ADR 
Total no. of participants n=151(%) 
Direct contact 139(92%) 
Post 0(%) 
Telephone 12(7.9%) 
Mail/website 0(%) 
 
 
 
Figure 10:  Distribution of preferred methods of ADR reporting 
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Table 13: Distribution of factors responsible for ADR reporting 
Factors that encourage you to 
report ADRs 
Total no. of participants n=151(%) 
Seriousness of reaction 9(6%) 
Unusualness of reaction 0(%) 
Involvement of new drug 0(%) 
Confidence in diagnosis of ADR 0(%) 
All of above 142(94%) 
 
 
Figure 11: Distribution of factors responsible for ADR reporting 
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Table 14: Factors that hinder ADR Reporting 
Factors that discourage you to 
report ADRs 
Total no. of participants n= 151 (%) 
Did not know how to report 14(9.2%) 
Do not think it important 3(1.9%) 
Managing patient was more 
important 
30(19.8%) 
Lack of access to ADR 
reporting form 
23(15.2%) 
Patient confidentiality issue 54(35.7%) 
ADR reporting is physicians’ 
duty 
0(%) 
Reporting is time consuming 13(8.6%) 
Legal liability issue 2(1.3%) 
All of above 12(7.9%) 
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Figure 12:  Factors that hinder ADR Reporting 
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8. DISCUSSION 
The objective of the study was to assess the knowledge, attitude and practice 
of pharmacovigilance and adverse drug reaction reporting among nursing staffs.  
The study was conducted in the multi speciality hospitals at Chennai.  300 
participants were randomly approached for collecting the data.  Out of 300, 150 
were responded.   
In present study total 300 questionnaires were distributed among nursing 
staffs who were working in different private multi speciality hospitals at Chennai. 
Out of 300 questionnaires, 151 were filled and return back it. In table 1, majority of 
study participants were female nursing staffs 144(95.3%) than male 7(4.63%). 
Similarly, women were found to be more interested in participating in surveys 
investigating drug safety issues.26 
Age wise distribution of study participants were presented in Table 2. 112 
(74.1%) study participants were present in the age group of 21-25 years, 26 (17.2%)    
participants in 26-30 years and least participants were 13(8.6%) in age group of 31 
and above. In previous study eighty-four percent of the participants were between20 
and 40 years of age which is similar to our study report. Therefore, young HCPs are 
likely more enthusiastic about ADR reporting systems.26In previous study male 
health care professionals were higher than female which is inconsistent with our 
study report.33 
 In table 3, majority of study participants 132(87.4%) had working experience 
of 1-5 years than 10(6.6%) had 6-10 years. Only 7(4.6%) nursing staffs had greater 
than 21 years of experience and 2(1.3%) participants had less than 1 years of 
experience which mean fresher. None of the participants were present in between 
11-15 and 16-20 years of experience. More than half (54%) of the study participants 
were at the early stages of their professional careers (up to five years of experience), 
which might explain the limited knowledge and awareness of the ADR reporting 
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system. However, many participants had more years of experience, and these 
participants had more knowledge regarding the ADR reporting system.26,33 
In table 4, 139(92%) participants had designation as nurse, 5(0.3%) as nurse 
specialists, 3(1.9%) as beginners/juniors, 2(0.1%) as senior nurse specialists and 
each 1(0.6%) as head of nurse and senior nurse. In another study by Ahmad et al., 
among 151 nursing staffs, 147(97.3%) have attend seminars/programmes related to 
pharmacovigilance and others 4(2.6%) have didn’t attend any programmes. Training 
professionals with prior exposure to pharmacovigilance practices could result in 
betteroutcomes.37 Strengthening the regular education and training of HCPs about 
pharmacovigilance and ADR reporting is a very important step towards improving 
the safety and quality of life of patients Alshammariet al., (2015).26 
There were 16 questions assessing knowledge regarding ADR. As shown in 
table 6,  30(19.8%) and 21 (13.9%) knew about the term pharmacovigilance and 
ADRs respectively, 151(100%)don’t knew about the types of ADR. Among 
respondents, 12(7.9%) knew where the International Centre for adverse drug 
reaction monitoring is located. Only 18(11.9%) were aware of the drugs that are 
banned due to ADR whereas 64(42.3%) knew the major risk factor for the 
occurrence of ADR. A small proportion of respondent 41(27.1%) knew where to 
report ADR in India and only 116(76.8%) knew about the formal reporting system 
in other countries. The majority of respondents 143(94.7%) did not share 
information regarding ADR to anyone, whereas 78(51.6%) respondents gathered 
information about ADR through the seminars, 15(9.9%) from textbooks, journals 
2(1.3%), medical representative 3(1.9%), internet 23(15.2%) and all of the above 
30(19.8%) respectively. None had collected from direct mail brochures. Among 
respondents, 21(13.9%) believed that side effects like a headache, vomiting and 
fever should never be reported. Only a small proportion of the respondents were 
aware of WHO online database for reporting ADR 12(7.9%). In India, 4(2.6%) 
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knew about which Regulatory body is responsible for monitoring of ADR’s. 
67(44.3%) knew about pharmacovigilance which includes drug related problems.  
Knowledge regarding ADR is very important when it comes to reporting 
ADR. It is very important for physicians as well as pharmacists to possess great 
knowledge of ADR and procedure of reporting ADR. The results showed that health 
care professionals have poor knowledge regarding ADR reporting which is in 
correspondence with studies conducted in other different cities of Pakistan which 
include Lahore, Abbottabad and Hyderabad, all these studies show poor knowledge 
of physicians and pharmacists regarding ADR reporting.38,39 Similar studies carried 
out in India showed poor knowledge of physicians and pharmacists regarding 
ADR.40A study carried out inIndia reveals that 41.6% were aware of the 
International Centre for ADR monitoring.41On the other hand, the studies conducted 
in India by Ghoshet al., and Gupta et al., showed that the healthcare professionals 
have high knowledge regarding ADR reporting but still the poor practice of 
ADR.42,43 
Many respondents could not identify the most appropriate source of 
information on ADR. According to the previous study, 31.9% physicians and 
pharmacists refer to the internet, 18.4% textbooks, 12.7% journals and 4.7% to 
seminars.24 
Attitude towards ADR reporting were presented in table 7. Majority of 
participants had given response as strongly agree for the questions like ADR 
reporting necessary 126(83.4%), ADR reporting should be mandatory136(90%), 
ADR reporting increase patient safety 131(86.7%), ADR is time consuming 
110(72.8%), Education programs have positive effect on ADRs reporting 148(98%), 
Do you think Pharmacovigilance should be taught in detail to healthcare 
professionals 151(100%) and least for Consulting the physician is important before 
report an ADR63(41.7%). Since most of the physicians and pharmacists consider 
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ADR reporting is necessary, they should overcome the obstacles in reporting ADR 
and report ADR voluntarily, whenever they encountered and should consider ADR 
reporting as their professional obligation.24 
131(86.7%),84(55.6%) had given response as agree for the questions Do you 
think it is necessary to confirm that an ADR is related to a particular drug before 
reporting it and With my present knowledge, I am very well prepared to report any 
ADRs notice in my future practice. Meanwhile 49(32.4%) given response as 
strongly disagree for I am very well prepared to report any ADRs notice in my 
future practice. This clearly shows that most of the nursing staffs had very good 
attitude towards ADR reporting and pharmacovigilance. Study by Desai et al., 
showed that 97.3% in India believe that ADR reporting increase patient safety.44 
59% of nursing staffs have reported ADR and 41% have never reported any 
ADR. Out of 89 ADR, 84(94.3%) were found to be severe, 51(57.3%) were mild 
and 26(29.2%) were moderate. None of the nursing staffs had ever done any 
interventions to prevent ADRs. The ADR reporting practice among physicians and 
pharmacists was far below than expectations. ADR has not been reporteddespite 
encountering ADR in their daily practice. One of the important findings of this study 
is the majority of respondents 88.3%never reported ADR. Only 11.7% reported 
ADR and those who have reported ADR did not report to the proper place, only 
9.1% respondents report ADR to the Ministry of Health.24 
Out of 151 participants, 119(78.8%) replied that ADR reporting center were 
colleagues/ immediate reporting, 20(13.2%) said head of department, 12(7.9%) said 
do not know. Itis evident from the study that physicians and pharmacists are not 
encouraged by their workplace to report ADR. The majority statedthat their 
workplace does not encourage them to report ADR and does not provide any 
information regarding ADR reporting. Alarge proportion of respondent stated that 
they have never been trained for reporting ADR.24Furthermore, different healthcare 
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professions were compared in this study, and pharmacists (77%) were found to be 
better informed regarding the NPC’s location; most physicians and nurses thought 
the NPC existed within the Ministry of Health. Knowledge, awareness, and practice 
are interrelated but might not always bereciprocal. In our study, a quite encouraging 
percentage (73%) of HCPs were aware of the ADR reporting system at their 
workplace; however, only 27% of the HCPs were able to report ADRs.95% of the 
participants responded that they would report ADR reactions for both old and newly 
marketed agents.26 
Among 151 nursing staffs, most of them 139(92%) had reported that direct contact 
as preferred method to report ADR and rest 12(7.9%) reported as telephone. 
Furthermore, only 22% of the participants were aware that the NPC was located at 
the SFDA. However, this lack of knowledge is not a major concern because HCPs 
can report ADRs online or viae-mail, postal mail, fax or phone, and all of these 
routes are accepted by the NPC as reporting methods.45 
Distribution of factors responsible for ADR reporting is presented in table 
12. 142(94%) reported as all of the above such as seriousness of reaction, 
unusualness of reaction, involvement of new drug, confidence in diagnosis of ADR. 
The remaining 9(6%) had reported as seriousness of reaction. Our study report is 
highly correlate with Nisha et al.24 
 Factors that discourage the respondents to report ADR include patient 
confidentiality issue 54(35.7%) and managing patient was more important 
30(19.8%). Some stated that lack of access to ADR reporting form 23(15.2%), did 
not know how to report 14(9.2%), reporting is time consuming13(8.6%), all of 
above 12(7.9%), do not think it important 3(1.9%), legal liability issue 2(1.3%). One 
of the findings of previous study is that lack of knowledge on how, where and whom 
to report ADR is one of the main reasons which discourages physicians and 
pharmacists to report ADR.24Whereas studies carried out in India by Shah et al., 
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revealed that lack of time is the main reason that discourages healthcare 
professionals to report ADR.46 
Previous studies around the world by Adhikaryet al., and Abubakaret al., 
emphasised great importance in providing awareness regarding ADR reporting and 
education interventions have a positive impact on increasing awareness regarding 
ADR reporting among healthcare professionals. Therefore it is very important to 
provide education and training to improve ADR reporting system.47,48 
According to a study by Bishtet al., in India, the healthcare professionals 
who have received educational training regarding ADR reporting hadadequate 
knowledge of pharmacovigilance and improved awareness regarding ADR.49 Proper 
education and training should be provided to healthcare professionals at regular 
interval to increase their knowledge regarding ADR reporting. Some other studies 
also confirmed that educational interventions lead to an increased awareness about 
ADR reporting (Li et al.,2004, Rajesh et al., 2011).9,50 Knowledgeand awareness of 
ADR reporting alone is not sufficient, and anemphasis on the practical involvement 
of HCPs in ADR reporting isrequired.51 
One of the main limitations, number of participants is very less. The findings 
should not be extrapolated to nursing staffs in other hospitals. It is necessary to 
extend this type of study to other hospitals in India to obtain more generalizable 
results. Knowledge and perception may vary on other locations. Therefore, its 
findings  cannot be generalized to the whole country. 
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9. CONCLUSION 
 The study discloses that nursing staffs have poor knowledge and poor 
practice but good in attitude towards ADR reporting. Even though they have 
reported more number of severe ADRs, they didn’t perform any further 
interventions to prevent it.  The major factor which discourages them from 
reporting ADR is a patient confidentiality issue and managing patient was 
more important. Seriousness of reaction, unusualness of reaction, 
involvement of new drug, confidence in diagnosis of ADR was the factors 
that encourage nursing staffs to report ADR. 
 Based on the outcomes of the present study following recommendations are 
concluded. ADR reporting forms should be freely available in all hospitals as 
it can improve the reporting rates of ADR in the country. ADR reporting 
should be mandatory for all healthcare professionals. Each hospital should 
have a database on ADR which should be considered by healthcare 
professionals. The nursing syllabus curriculum needs to be revised to include 
ADR and pharmacovigilance. Continuous education programme and 
workshop want to be conducted regularly relate to how and where to report 
ADR. 
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ethics committee in its meeting held on 17.01.2018and permission is 
granted to you to carry out the study. 
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          Dr. A. Sivakumar 
Chairman of Ethics Committee 
  
 
 
INFORMATION FOR PATIENT 
 
Dear participant, 
I am a post graduate student of ‘JKK Nattraja College of Pharmacy’ 
currently conducting a project entitled “Assessment of knowledge, attitude and 
practice of pharmacovigilance and adverse drug reaction reporting among 
nursing staffs”. 
For this, am requesting you to fill the structured questionnaire. No 
identifiable personal data’s will be disclosed. 
Thank you very much for your kind participation. 
 
CONSENT FORM 
 
 I, have read and understand the above information. I have agreed to allow 
my data to be collected for the project work.      
 
 
 
 
Signature of participant                                                          Date                                                          
 
 
  
QUESTIONNAIRE 
Age:                                                    Gender: Male / Female 
       
Name of the working hospital:  
Are you aware of any pharmacovigilance program? Yes/no 
I. Knowledge towards ADR 
1. Define pharmacovigilance? 
a) The science of monitoring ADR’s happening in a hospital  
b) The process of improving the safety of drugs  
c) The detection, assessment, understanding and prevention of adverse effects  
d) The science detecting the type and incidence of ADR after the drug is 
marketed  
e) Do not know  
2.  Define ADR? 
a) Noxious and unintended response to drug and occurs at doses normally used in 
man or animal for prophylaxis, diagnosis or therapy of disease 
b) Noxious and unintended response to drug and occurs at doses normally used in 
man for prophylaxis, diagnosis and therapy of disease  
c) Any untoward medical occurrence that may present during treatment with a 
medicine but which does not necessarily have a causal relationship with this 
treatment 
d) Any adverse reaction identified in regulatory documents such as investigators 
brochures or product monograph occurring within the expected frequency 
e) Do not know  
3.  Are you aware of any formal reporting system available in other countries 
a) Yes  
b) NO  
  
4.  Are you aware of any drug that has been banned in the world due to ADR? 
a) Yes  
b) No  
c) Do not know  
5.  Have you ever shared information about ADRs with anyone? 
a) Yes  
b) No  
6.  Where is an international centre for adverse effect reaction monitoring located? 
a) Sweden  
b) Germany  
c) USA  
d) Do not know  
7.  Which of the following is a major risk factor for the occurrence of maximum 
adverse drug reactions? 
a) Arthritis  
b) Renal failure  
c) Visual impairment  
d) All of these  
e) Do not know  
8.  Are you aware of any of the below reporting centre or system in India where you 
can report ADR? 
a) Madras Medical College, Chennai  
b) Christian Medical College, Vellore 
c) PSG institute, Coimbatore 
d) Govt. Kilpauk Medical College, Chennai  
e) Ministry of health  
f) No centre for reporting  
g) Do not know  
  
9.  Identify the types of ADR’s?  
a) Type A, B, C, D, E, F and G  
b) Type 1, 2, 3, 4, 5, 6 and 7  
c) Known, unknown and common, uncommon  
d) Reversible and irreversible  
e) Do not know  
10.  Which one of the following is the WHO online database for reporting ADR’s? 
a) ADR advisory committee  
b) Med safe  
c) Vigibase 
d) Med watch  
e) Do not know  
11.  From which sources do you gather information about ADRs to new drugs? 
a) Textbooks  
b) Journals  
c) Internet  
d) Medical representatives  
e) Seminars/conferences  
f) Direct mail brochures  
g) All of the above  
12.  Side effects like headache fever and vomiting should not be reported? 
a) Strongly agree  
b) Agree  
c) Disagree  
d) Strongly disagree  
13. What to report:  
a) Serious adverse event (SAE)  
b) Adverse Event  
c) Adverse drug reaction (ADR)  
d) Side Effect  
e) All  
f) Not know  
14.Which ADR should be reported 
a) All serious ADRs 
b) ADRs to herbal and non-allopathic drugs 
c) ADRs to new drugs 
d) ADRs to vaccines 
e) Unknown ADRs to odd drugs 
f) All of the above 
15. In India which Regulatory body is responsible for monitoring of ADR’s?  
a) Central Drugs Standard Control Organization*  
b) Indian Institute of sciences  
c) Pharmacy Council of India  
d) Medical Council of India 
16. Pharmacovigilance includes  
a) Drug related problems  
b) Blood related products  
c) Herbal products  
d) All of the above* 
II. Attitude towards ADR reporting    
 ADR reporting    (Put 
tick) 
Strongly agree Agree Disagree Strongly 
disagree 
ADR reporting necessary      
ADR reporting should be 
mandatory  
    
ADR reporting increase 
patient safety   
    
ADR is time consuming      
Do you think it isnecessary 
to confirmthat an ADR is 
related toa particular drug 
    
beforereporting it? 
Education programs have 
positive effect on ADRs 
reporting 
    
Consulting the physician is 
important before report an 
ADR 
    
With my 
presentknowledge, I am 
verywell prepared to 
reportany ADRs notice in 
myfuture practice. 
    
Do you think 
Pharmacovigilance should 
be taught in detail to  
healthcare professionals? 
    
 
1. Why it is important to report ADR 
a) To identify and detect new ADR 
b) To share information about ADRs with colleagues 
c) To improve patient safety 
d) To identify relative safe drugs 
e) To measure the incidence of ADRs 
 
2. What factors do you think are important whole deciding to report an ADR? 
a) Unusualness of the reaction 
b) Involvement of a new drug 
c) Confidence in diagnosing of an ADR 
  
III. Practice towards ADR reporting    
1. Have you reported an ADR?  Yes/No 
 
2. ADR reported per week 
a) 0-5/week 
b) 6-10/week 
c) More than 10/week 
 
3. ADR reporting centre 
a) Concerned pharmaceutical company 
b) Head of department  
c) Ministry of health 
d) Don’t know 
 
4. Nature  of ADR reported  
a) Severe 
b) Moderate 
c) Mild 
d) All of the above 
 
5. Preferred method to report ADR 
a) Direct contact 
b) Post 
c) Telephone 
d) Mail/website 
 
6. Professional responsible to report ADR 
a) Physicians 
b) Pharmacist 
c) Both physicians and pharmacists 
 
7. List the common ADR that you have reported 
8. Have you done any intervention to prevent ADRs? Yes/no 
IV. Factors that encourage you to report ADRs 
a) Seriousness of reaction 
b) Unusualness of reaction 
c) Involvement of new drug 
d) Confidence in diagnosis of ADR 
e) All of above 
 
V. Factors that discourage you to report ADRs 
a) Did not know how to report 
b) Not knowing where to report 
c) Do not think it important 
d) Managing patient was more important 
e) Lack of access to ADR reporting form 
f) Patient confidentiality issue 
g) ADR reporting is physicians’ duty 
h) Reporting is time consuming 
i) Legal liability issue 
j) All of above 
 
 
 
